(1) Elucidation of the structural defect of HE, HPP spectrin (Sp). Three molecular defects of the yield I domain of Sp, the SpD-SpD self-association site, have been identified by us and others in HPP and a subpopulation of HE. These are characterized by a formation of 74, 65 and 46 kd tryptic peptides generated instead of the normal 80 kd yield I peptide. To elucidate the structure of these Sp and their possible heterogeneity, we will subject the abnormal peptides to further chemical or enzymatic cleavage, followed by HPLC peptide separation. Abnormal peptides will be subjected to amino acid sequence analysis to identify the primary structural defect. We will also employ other enzymatic and chemical cleavages to generate peptides containing the trypsin sensitive sites (the presumptive site of the primary structural defect). Employing a similar strategy we will further characterize recently identified asymptomatic variants of Sp yield III and Beta II domains and recently detected HE(SpD-SpD), with no identifiable abnormalities on limited tryptic peptide maps. (2) Genetics of the Sp I in HE and HPP. Based on functional, structural and clinical expression of the Sp yield defects, we distinguish at least 3 clinical phenotypes: asymptomatic carriers, whose red cells contain about 25% of abnormal Sp, HE containing 40-50% and HPP containing 75-100% of abnormal Sp, respectively.
Our aim i s to define factors that determine the above phenotypes including: (i) instability of HPP Sp, (ii) compound heterozygous state for a structural Sp defect and a variably expressed defect of SP synthesis, and (iii) possible duplication of allelic yield Sp genes. In the latter case, the differences in clinical phenotype may be due to involvement of one, two, three or four of the four SP genes, respectively. To study those hypothetical factors we will (a) provide quantitative analysis of normal and abnormal Sp in the cells, (b) measure relative synthetic rates of yield, Beta Sp in reticulocytes and red cell precursors and Sp mRNA content, and (c) examine the susceptibility of normal and abnormal Sp to proteolytic degradation in bone marrow precursors. (3) Identification of molecular defects in other HE and HS patients. In a subpopulation of HE (11 kindred out of 46) and in all 12 HS kindred studied to date, we find neither a deficiency of one of the major proteins on SDS PAGE, nor a qualitative defect of Spd-Spd. In some of these, we studied patient Sp-control 4.1 and patient Sp-control IOV interaction and found them to be normal. To search for a putative molecular defect in these patients we plan (a) to employ sensitive screening assays to measure Sp-4.1 and Sp-ankyrin, ankyrin-band 3 interactions, (b) to analyze limited tryptic and chymotryptic peptides of 4.1 and ankyrin, (c) to look for a possible deficiency of one of the minor skeletal proteins, and (d) study Sp, 4.1 interactions with PS, PE, the major phospholipids of the inner membrane bilayer.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
2R37HL027215-06
Application #
3485893
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1981-06-01
Project End
1991-05-31
Budget Start
1986-06-01
Budget End
1987-05-31
Support Year
6
Fiscal Year
1986
Total Cost
Indirect Cost
Name
St. Elizabeth's Medical Center of Boston
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02135
Hanspal, M; Smockova, Y; Uong, Q (1998) Molecular identification and functional characterization of a novel protein that mediates the attachment of erythroblasts to macrophages. Blood 92:2940-50
Yi, S J; Liu, S C; Derick, L H et al. (1997) Red cell membranes of ankyrin-deficient nb/nb mice lack band 3 tetramers but contain normal membrane skeletons. Biochemistry 36:9596-604
Jarolim, P; Murray, J L; Rubin, H L et al. (1997) Blood group antigens Rb(a), Tr(a), and Wd(a) are located in the third ectoplasmic loop of erythroid band 3. Transfusion 37:607-15
Jarolim, P; Murray, J L; Rubin, H L et al. (1997) A Thr552 -->Ile substitution in erythroid band 3 gives rise to the Warrior blood group antigen. Transfusion 37:398-405
Hassoun, H; Vassiliadis, J N; Murray, J et al. (1997) Characterization of the underlying molecular defect in hereditary spherocytosis associated with spectrin deficiency. Blood 90:398-406
Hassoun, H; Palek, J (1996) Hereditary spherocytosis: a review of the clinical and molecular aspects of the disease. Blood Rev 10:129-47
Wichterle, H; Hanspal, M; Palek, J et al. (1996) Combination of two mutant alpha spectrin alleles underlies a severe spherocytic hemolytic anemia. J Clin Invest 98:2300-7
Hassoun, H; Vassiliadis, J N; Murray, J et al. (1996) Hereditary spherocytosis with spectrin deficiency due to an unstable truncated beta spectrin. Blood 87:2538-45
Jarolim, P; Murray, J L; Rubin, H L et al. (1996) Characterization of 13 novel band 3 gene defects in hereditary spherocytosis with band 3 deficiency. Blood 88:4366-74
Jarolim, P; Rubin, H L; Brabec, V et al. (1995) Mutations of conserved arginines in the membrane domain of erythroid band 3 lead to a decrease in membrane-associated band 3 and to the phenotype of hereditary spherocytosis. Blood 85:634-40

Showing the most recent 10 out of 50 publications